Decitabine combined regimen in the therapy of Blastic plasmacytoid dendritic cell neoplasm: case report
Keyword(s):
We enrolled a patient diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) . We have found that TET2, KRAS and BRAF may be involved in the development of the disease, and the combination therapy of Decitabine (DAC) and Arsenic acid (ASO) may be effective for BPDCN harboring the TET2 mutations.
Keyword(s):
2018 ◽
Vol 79
(3)
◽
pp. AB58
2013 ◽
Vol 140
(suppl 1)
◽
pp. A135-A135
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2011 ◽
Vol 207
(1)
◽
pp. 55-59
◽